Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 7
1981 5
1982 7
1983 13
1984 16
1985 24
1986 13
1987 16
1988 38
1989 72
1990 90
1991 96
1992 107
1993 97
1994 120
1995 137
1996 131
1997 125
1998 124
1999 122
2000 129
2001 117
2002 129
2003 108
2004 111
2005 119
2006 120
2007 116
2008 113
2009 122
2010 121
2011 117
2012 134
2013 126
2014 130
2015 133
2016 105
2017 101
2018 86
2019 108
2020 109
2021 123
2022 96
2023 100
2024 52

Text availability

Article attribute

Article type

Publication date

Search Results

3,863 results

Results by year

Filters applied: . Clear all
Page 1
Leuprorelin acetate in prostate cancer: a European update.
Persad R. Persad R. Int J Clin Pract. 2002 Jun;56(5):389-96. Int J Clin Pract. 2002. PMID: 12137449 Review.
This review provides an update on leuprorelin acetate, the world's most widely prescribed depot luteinising hormone-releasing hormone analogue. Leuprorelin acetate has been in clinical use in the palliative treatment of prostate cancer for more than 20 …
This review provides an update on leuprorelin acetate, the world's most widely prescribed depot luteinising hormone-releasing …
Leuprolide acetate: a drug of diverse clinical applications.
Wilson AC, Meethal SV, Bowen RL, Atwood CS. Wilson AC, et al. Expert Opin Investig Drugs. 2007 Nov;16(11):1851-63. doi: 10.1517/13543784.16.11.1851. Expert Opin Investig Drugs. 2007. PMID: 17970643 Review.
As its basic mechanism of action, leuprolide acetate suppresses gonadotrope secretion of luteinizing hormone and follicle-stimulating hormone that subsequently suppresses gonadal sex steroid production. In addition, leuprolide acetate is presently bein …
As its basic mechanism of action, leuprolide acetate suppresses gonadotrope secretion of luteinizing hormone and follicle-stim …
Leuprorelin acetate granulomas: case reports and review of the literature.
Yasukawa K, Sawamura D, Sugawara H, Kato N. Yasukawa K, et al. Br J Dermatol. 2005 May;152(5):1045-7. doi: 10.1111/j.1365-2133.2005.06341.x. Br J Dermatol. 2005. PMID: 15888168 Review.
Leuprorelin acetate, an agonist of gonadotropin-releasing hormone (GnRH), is indicated in the treatment of prostate cancer. Recently, depot formulations of leuprorelin acetate have been widely used. We report three patients who showed a granulomatous r …
Leuprorelin acetate, an agonist of gonadotropin-releasing hormone (GnRH), is indicated in the treatment of prostate cancer. Re …
Advanced delivery of leuprorelin acetate for the treatment of prostatic cancer.
Merseburger AS, Roesch MC. Merseburger AS, et al. Expert Rev Anticancer Ther. 2022 Jul;22(7):703-715. doi: 10.1080/14737140.2022.2082947. Epub 2022 Jun 3. Expert Rev Anticancer Ther. 2022. PMID: 35612551
Due to its favorable tolerability among different treatments available for ADT, leuprorelin acetate is well established as the leading luteinizing hormone-releasing hormone (LHRH) analog. The development of second-generation leuprorelin acetate (LA) de …
Due to its favorable tolerability among different treatments available for ADT, leuprorelin acetate is well established as the …
Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation.
Tunn UW, Gruca D, Bacher P. Tunn UW, et al. Clin Interv Aging. 2013;8:457-64. doi: 10.2147/CIA.S27931. Epub 2013 Apr 26. Clin Interv Aging. 2013. PMID: 23637525 Free PMC article. Review.
For nearly three decades, gonadotropin-releasing hormone (GnRH) agonists, particularly leuprorelin acetate (LA), have served as an important part of the treatment armamentarium for prostate cancer. ...The literature search identified 14 publications; by excluding re …
For nearly three decades, gonadotropin-releasing hormone (GnRH) agonists, particularly leuprorelin acetate (LA), have served a …
Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer.
Sethi R, Sanfilippo N. Sethi R, et al. Clin Interv Aging. 2009;4:259-67. doi: 10.2147/cia.s4885. Epub 2009 Jun 9. Clin Interv Aging. 2009. PMID: 19554097 Free PMC article. Review.
Recently, a 6-month depot leuprorelin has been approved for use in advanced and metastatic prostate cancer patients. With similar efficacy and side effect profiles to earlier formulations, 6-month depot leuprorelin is a convenient treatment option for these patients …
Recently, a 6-month depot leuprorelin has been approved for use in advanced and metastatic prostate cancer patients. With similar eff …
[Leuprorelin acetate depot].
Mashimo T. Mashimo T. Nihon Rinsho. 2000 Jul;58 Suppl:191-6. Nihon Rinsho. 2000. PMID: 11022712 Review. Japanese. No abstract available.
Life-threatening anaphylaxis to leuprorelin acetate depot: case report and review of the literature.
Fujisaki A, Kondo Y, Goto K, Morita T. Fujisaki A, et al. Int J Urol. 2012 Jan;19(1):81-4. doi: 10.1111/j.1442-2042.2011.02886.x. Epub 2011 Nov 3. Int J Urol. 2012. PMID: 22050405 Review.
Most of the side/adverse effects of gonadotropin-releasing hormone analog depots, such as leuprorelin acetate depot, are related to hypotestosteronism in males. ...A drug-lymphocyte stimulation test showed that not only leuprorelin acetate itself, but …
Most of the side/adverse effects of gonadotropin-releasing hormone analog depots, such as leuprorelin acetate depot, are relat …
Ulipristal acetate compared with leuprorelin acetate for Japanese women with symptomatic uterine fibroids: a phase III randomized controlled trial.
Osuga Y, Nakano Y, Yamauchi Y, Takanashi M. Osuga Y, et al. Fertil Steril. 2021 Jul;116(1):189-197. doi: 10.1016/j.fertnstert.2021.01.023. Epub 2021 Mar 11. Fertil Steril. 2021. PMID: 33715871 Free article. Clinical Trial.
OBJECTIVE: To evaluate the efficacy and safety of ulipristal acetate (UPA) for uterine fibroids (UFs), a phase III study was conducted with leuprorelin (LEU) as a comparator. ...
OBJECTIVE: To evaluate the efficacy and safety of ulipristal acetate (UPA) for uterine fibroids (UFs), a phase III study was conducte …
A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma.
Fushimi C, Tada Y, Takahashi H, Nagao T, Ojiri H, Masubuchi T, Matsuki T, Miura K, Kawakita D, Hirai H, Hoshino E, Kamata S, Saotome T. Fushimi C, et al. Ann Oncol. 2018 Apr 1;29(4):979-984. doi: 10.1093/annonc/mdx771. Ann Oncol. 2018. PMID: 29211833 Free PMC article. Clinical Trial.
PATIENTS AND METHODS: We conducted a single institution, open-label, single arm, phase II trial of combined androgen blockade (CAB) for androgen receptor (AR)-positive SGC. Leuprorelin acetate was administered subcutaneously at a dose of 3.75 mg every 4 weeks. ...El …
PATIENTS AND METHODS: We conducted a single institution, open-label, single arm, phase II trial of combined androgen blockade (CAB) for andr …
3,863 results

Searches related to "leuprorelin acetate"